Fluorination of bioactive compounds
Lead Research Organisation:
University of Southampton
Department Name: Sch of Chemistry
Abstract
This is a synthetic organic chemistry project, dealing with the synthesis of fluorinated bioactive compounds. The project fits in a larger research program in our group, and the choice of modifications is guided byour recent work in how physical properties of organic molecules can be modified by targeted fluorination, and how these effects can be explained and predicted (key papers: Angew. Chem. Int.Ed.2012, 51, 6176 (VIP); Chem. Eur. J. 2014, 20, 106;J. Am. Chem. Soc.2015, 137, 1230; Chem. Eur. J. 2015, 21, 17808; Angew. Chem. Int. Ed.2015, in press (VIP)).
People |
ORCID iD |
| Bruno Linclau (Primary Supervisor) | |
| David Evans (Student) |
Studentship Projects
| Project Reference | Relationship | Related To | Start | End | Student Name |
|---|---|---|---|---|---|
| EP/N509747/1 | 01/10/2016 | 30/09/2021 | |||
| 1795539 | Studentship | EP/N509747/1 | 01/10/2016 | 30/09/2019 | David Evans |
| Description | We have identified bioactive compounds for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; or liver damage arising from fibrosis |
| Exploitation Route | Further development of the discovered bioactive |
| Sectors | Other |
| Description | Further development of the discovered bioactives |
| Sector | Pharmaceuticals and Medical Biotechnology,Other |
| Title | FLUORINATED BILE ACID DERIVATIVES |
| Description | Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; or liver damage arising from fibrosis. |
| IP Reference | WO2020025942 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | Commercial In Confidence |
| Impact | in progress |